Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

362 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Younes A, et al. Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31. Lancet Oncol. 2016. PMID: 27049457 Free PMC article. Clinical Trial.
Efficacy and side effect profile of two CMV prophylaxis strategies in high and intermediate risk kidney transplant recipients - a multicentre national study.
Rennie TJW, Geddes CG, McIntyre-McClure R, Chua BHE, Metcalfe W, Johannessen I, Phelan PJ; SCOT-network C. M. V. prophylaxis working group. Rennie TJW, et al. J Nephrol. 2021 Dec;34(6):2173-2175. doi: 10.1007/s40620-021-01161-4. Epub 2021 Nov 16. J Nephrol. 2021. PMID: 34782970 No abstract available.
Spectroscopic molecular-fingerprint profiling of saliva.
Buchan E, Kelleher L, Clancy M, Stanley Rickard JJ, Oppenheimer PG. Buchan E, et al. Among authors: clancy m. Anal Chim Acta. 2021 Nov 15;1185:339074. doi: 10.1016/j.aca.2021.339074. Epub 2021 Sep 18. Anal Chim Acta. 2021. PMID: 34711319 Free article.
362 results